Cardinal Health, Inc. CAH SPX
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits. Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Profit CAGR of 88.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CAH Cardinal Health, Inc. SPX | 196.80 | 30.05 | $46.09B | 1.04% | 16.28% | - | 7.07% | 88.81% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.55B | 28.05B | 31.45B | 30.66B | 31.38B | 32.04B | 33.15B | 31.82B | 32.97B | 32.64B | 35.19B | 33.63B | 35.35B | 35.21B | 37.74B | 35.23B | 37.35B | 37.34B | 39.73B | 39.16B | 36.69B | 39.06B | 41.54B | 39.27B | 43.97B | 45.46B | 44.84B | 49.59B | 51.47B | 50.50B | 54.65B | 57.44B | 54.87B | - | - | 54.88B | 60.16B | 64.01B | 65.63B | 60.94B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.76B | 57.96B | 61.69B | 63.23B | 58.44B |
| Gross Profit | 1.46B | 1.58B | 1.61B | 1.69B | 1.67B | 1.59B | 1.60B | 1.73B | 1.62B | 1.67B | 1.86B | 1.91B | 1.74B | 1.67B | 1.73B | 1.76B | 1.67B | 1.68B | 1.71B | 1.89B | 1.59B | 1.72B | 1.78B | 1.81B | 1.64B | 1.62B | 1.68B | 1.60B | 1.68B | 1.81B | 1.74B | 1.85B | 1.94B | - | - | 2.12B | 2.20B | 2.32B | 2.40B | 2.50B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.47B | 1.62B | 1.56B | 1.63B | 1.66B |
| Operating Income | - | 620.00M | 563.00M | 656.00M | - | 535.00M | 542.00M | 605.00M | - | 262.00M | 399.00M | 546.00M | - | 816.00M | 504.00M | 432.00M | - | -5.26B | 334.00M | 562.00M | - | -624.00M | 461.00M | 473.00M | 415.00M | -950.00M | -97.00M | 123.00M | -86.00M | 604.00M | -32.00M | 505.00M | 369.00M | - | - | 656.00M | 585.00M | 754.00M | 763.00M | 842.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 946.00M | 667.00M | 911.00M | 952.00M | 741.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.00M | 74.00M | 80.00M | 88.00M | 101.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 665.00M | 384.00M | 598.00M | 630.00M | 392.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 157.00M | 141.00M | 144.00M | 159.00M | 12.00M |
| Net Income | 295.00M | 383.00M | 326.00M | 386.00M | 333.00M | 309.00M | 324.00M | 381.00M | 274.00M | 115.00M | 1.05B | 255.00M | -1.17B | 593.00M | 280.00M | 296.00M | 194.00M | -4.92B | 220.00M | 350.00M | 656.00M | -253.00M | 629.00M | 119.00M | 271.00M | 49.00M | -1.39B | 98.00M | -77.00M | 365.00M | -12.00M | 368.00M | 261.00M | - | - | 506.00M | 239.00M | 450.00M | 467.00M | 399.00M |
| Diluted EPS | - | 1.15 | 0.98 | 1.17 | - | - | - | - | - | - | - | - | - | 1.94 | - | - | - | -16.65 | - | - | - | -0.86 | - | - | 0.94 | - | - | 0.36 | -0.30 | 1.41 | -0.05 | 1.50 | 1.07 | - | - | 2.10 | 1.00 | 1.88 | 1.97 | 1.69 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 95.99B | 98.50B | 102.64B | 107.55B | 101.09B | 91.08B | 102.53B | 121.55B | 129.98B | 136.81B | 145.53B | 152.92B | - | 181.33B | 204.98B | 226.83B | 222.58B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 174.84B | 198.10B | 219.41B | 214.41B |
| Gross Profit | 3.75B | 3.78B | 4.16B | 4.54B | 4.92B | 5.16B | 5.71B | 6.54B | 6.54B | 7.18B | 6.83B | 6.87B | - | 6.48B | 6.87B | 7.41B | 8.17B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.84B | 5.08B | 5.28B | 5.85B |
| Operating Income | 1.29B | 1.31B | 1.51B | 1.79B | 996.00M | 1.89B | 2.16B | 2.46B | 2.12B | 126.00M | 2.06B | -4.10B | - | 1.65B | 1.79B | 2.13B | 2.32B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.00M | 1.44B | 1.96B | 3.11B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 147.00M | 84.00M | 51.00M | 215.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -784.00M | 663.00M | 1.20B | 2.10B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 153.00M | 332.00M | 348.00M | 532.00M |
| Net Income | 1.15B | 642.00M | 959.00M | 1.07B | 334.00M | 1.17B | 1.22B | 1.43B | 1.29B | 256.00M | 1.36B | -3.70B | - | -938.00M | 330.00M | 852.00M | 1.56B |
| Diluted EPS | 3.18 | 1.77 | 2.72 | 3.06 | 0.97 | 3.38 | 3.62 | 4.32 | 4.03 | 0.81 | 4.53 | -12.61 | - | -3.35 | 1.00 | 3.45 | 6.45 |
Compounded Sales Growth
| 5 Years: | 7.07% |
| 1 Year: | 11.00% |
Compounded Profit Growth
| 5 Years: | 88.81% |
| 1 Year: | -19.50% |
Stock Price Performance
| 1 Year: | +28.87% |
| 6 Months: | -7.47% |
| 3 Months: | -13.94% |
| 1 Month: | -2.97% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 19.99B | 22.85B | 24.26B | 25.82B | 26.03B | 30.14B | 34.12B | 40.11B | 39.95B | 40.96B | 40.77B | - | 43.88B | 43.35B | 45.12B | 53.12B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.94B | 33.74B | 34.88B | 36.37B |
| Cash & Equivalents | 808.80M | 1.22B | 2.75B | 1.93B | 2.27B | 1.90B | 2.87B | 4.62B | 2.36B | 6.88B | 1.76B | 2.53B | 2.77B | - | 4.72B | 4.08B | 5.13B | 3.87B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.64B | 16.12B | 14.96B | 16.83B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.56B | 11.11B | 12.08B | 13.24B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.58B | 46.31B | 48.33B | 55.76B |
| Current Liabilities | - | - | 11.54B | 13.37B | 14.17B | 14.59B | 15.12B | 17.24B | 19.70B | 21.22B | 22.89B | 24.11B | 23.61B | - | 30.55B | 33.74B | 35.64B | 38.90B |
| Long Term Debt | - | - | 2.13B | 2.50B | - | - | - | - | - | - | - | - | - | - | 4.74B | 3.91B | 4.66B | 7.98B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.32B | 4.70B | 5.09B | 8.53B |
| Total Equity | 7.75B | 8.72B | 5.28B | 5.85B | 6.24B | 5.97B | 6.40B | 6.26B | 6.55B | 6.81B | 6.06B | 6.33B | 1.79B | - | -709.00M | -2.96B | -3.21B | -2.78B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 327.00M | 327.00M | 327.00M | 270.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.42B | 2.13B | 1.40B | 1.18B | 1.73B | 2.52B | 2.54B | 2.97B | 1.18B | 2.77B | 2.72B | 1.96B | - | 3.17B | 2.84B | 3.76B | 2.40B |
| Investing Cash Flow | -542.90M | 127.00M | -2.03B | -377.00M | -2.38B | -850.00M | -849.00M | -4.08B | -405.00M | -5.61B | 338.00M | 493.00M | - | 567.00M | -454.00M | -1.85B | -5.59B |
| Financing Cash Flow | -468.20M | -727.00M | -193.00M | -454.00M | 275.00M | -710.00M | 60.00M | -1.14B | 3.75B | -2.28B | -2.29B | -2.20B | - | -2.46B | -3.05B | -847.00M | 1.94B |
| Capital Expenditure | -421.20M | -260.00M | -291.00M | -260.00M | -195.00M | -249.00M | -300.00M | -465.00M | -387.00M | -384.00M | -328.00M | -375.00M | - | -387.00M | -481.00M | -511.00M | -547.00M |
| Free Cash Flow | 1.00B | 1.87B | 1.10B | 916.00M | 1.53B | 2.27B | 2.24B | 2.51B | 797.00M | 2.38B | 2.39B | 1.58B | - | 2.79B | 2.36B | 3.25B | 1.85B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.28B | -661.00M | 1.07B | -1.26B |
| Share Buybacks | 0 | 230.00M | 270.00M | 450.00M | 450.00M | 673.00M | 1.04B | 651.00M | 600.00M | 550.00M | 600.00M | 350.00M | 200.00M | 1.00B | 2.00B | 750.00M | 765.00M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 3.9% | 3.8% | 4.1% | 4.2% | 4.9% | 5.7% | 5.6% | 5.4% | 5.0% | 5.2% | 4.7% | 4.5% | - | 3.6% | 3.4% | 3.3% | 3.7% |
| Operating Margin % | 1.3% | 1.3% | 1.5% | 1.7% | 1.0% | 2.1% | 2.1% | 2.0% | 1.6% | 0.1% | 1.4% | -2.7% | - | 0.9% | 0.9% | 0.9% | 1.0% |
| Net Margin % | 1.2% | 0.7% | 0.9% | 1.0% | 0.3% | 1.3% | 1.2% | 1.2% | 1.0% | 0.2% | 0.9% | -2.4% | - | -0.5% | 0.2% | 0.4% | 0.7% |
| ROE % | 13.2% | 12.2% | 16.4% | 17.1% | 5.6% | 18.2% | 19.4% | 21.8% | 18.9% | 4.2% | 21.5% | -206.6% | - | 132.3% | -11.2% | -26.5% | -56.1% |
| ROCE % | - | 15.5% | 16.0% | 17.8% | 8.9% | 17.3% | 16.8% | 17.1% | 11.2% | 0.7% | 12.2% | -23.9% | - | 12.4% | 18.6% | 22.5% | 16.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.17% | 28.49M | $5.61B |
| 2 | Vanguard Capital Management LLC | 6.53% | 15.29M | $3.01B |
| 3 | Vanguard Portfolio Management LLC | 5.86% | 13.73M | $2.70B |
| 4 | State Street Corporation | 5.16% | 12.07M | $2.38B |
| 5 | Geode Capital Management, LLC | 2.81% | 6.58M | $1.30B |
| 6 | Morgan Stanley | 2.12% | 4.95M | $975.01M |
| 7 | Wellington Management Group, LLP | 1.83% | 4.28M | $841.55M |
| 8 | FMR, LLC | 1.81% | 4.24M | $835.07M |
| 9 | WCM Investment Management, LLC | 1.71% | 4.01M | $788.51M |
| 10 | Invesco Ltd. | 1.50% | 3.51M | $691.21M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CAH